Profile data is unavailable for this security.
About the company
Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.
- Revenue in EUR (TTM)6.15bn
- Net income in EUR1.07bn
- Incorporated2011
- Employees9.38k
- LocationUcb SAAllee de la Recherche, 60ANDERLECHT 1070BelgiumBEL
- Phone+32 25599999
- Fax+32 25599900
- Websitehttps://www.ucb.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Otsuka Holdings Co Ltd | 13.83bn | 2.03bn | 20.90bn | 35.34k | 10.24 | 1.33 | 7.81 | 1.51 | 650.78 | 650.78 | 4,433.96 | 5,000.59 | 0.6701 | 2.29 | 5.03 | 67,722,650.00 | 9.92 | 5.91 | 12.38 | 7.27 | 72.20 | 69.18 | 14.81 | 9.89 | 1.44 | -- | 0.0859 | 32.93 | 15.42 | 10.78 | 182.13 | 21.96 | 15.32 | 3.71 |
| Sandoz Group AG | 8.96bn | 0.00 | 21.33bn | 23.41k | -- | 2.96 | 49.11 | 2.38 | -0.0013 | -0.0013 | 19.37 | 15.25 | -- | -- | -- | 356,869.60 | -- | -- | -- | -- | 47.44 | -- | 0.0096 | -- | 0.7929 | 1.22 | 0.3736 | -- | 4.06 | -- | -100.00 | -- | -- | -- |
| Hansoh Pharmaceutical Group Company Ltd | 1.47bn | 523.95m | 22.49bn | 8.99k | 42.93 | 6.53 | 39.31 | 15.31 | 0.8036 | 0.8036 | 2.25 | 5.28 | 0.379 | 1.82 | 3.87 | 1,491,351.00 | 13.51 | 11.36 | 15.86 | 13.27 | 90.89 | 90.68 | 35.66 | 30.80 | 9.94 | -- | 0.0041 | 28.12 | 21.35 | 7.15 | 33.39 | 11.33 | -5.71 | -- |
| Bayer AG | 46.58bn | -3.25bn | 27.48bn | 90.89k | -- | 0.8469 | 4.91 | 0.5899 | -3.31 | -3.31 | 47.41 | 33.03 | 0.4067 | 1.64 | 3.39 | 501,847.80 | -2.83 | -2.66 | -3.81 | -3.61 | 53.99 | 57.98 | -6.96 | -6.88 | 0.792 | 2.54 | 0.5473 | -- | -2.16 | 1.37 | 13.23 | -- | 0.9479 | -47.66 |
| UCB SA | 6.15bn | 1.07bn | 33.84bn | 9.38k | 31.74 | 3.30 | 20.51 | 5.50 | 5.48 | 5.48 | 31.62 | 52.77 | 0.3741 | 1.50 | 4.48 | 656,003.40 | 6.48 | 4.98 | 7.97 | 6.20 | 71.52 | 71.71 | 17.31 | 13.00 | 0.9858 | 8.91 | 0.2319 | 34.22 | 17.14 | 4.60 | 210.50 | 6.16 | 1.84 | 2.31 |
| Alnylam Pharmaceuticals, Inc. | 2.02bn | -231.98m | 36.41bn | 2.23k | -- | 366.53 | -- | 18.03 | -2.09 | -2.09 | 18.27 | 0.8858 | 0.5842 | 4.12 | 9.70 | 1,052,959.00 | -6.71 | -20.07 | -8.96 | -25.51 | 86.01 | 84.18 | -11.49 | -55.19 | 2.98 | -0.4627 | 0.8988 | -- | 22.97 | 59.21 | 36.82 | -- | -24.55 | -- |
| Haleon PLC | 12.96bn | 1.66bn | 37.18bn | 24.00k | 22.84 | 2.01 | -- | 2.87 | 0.1571 | 0.1571 | 1.22 | 1.79 | 0.3286 | 3.39 | 5.49 | 468,041.70 | 4.31 | 3.67 | 5.11 | 4.23 | 60.75 | 62.28 | 13.13 | 11.97 | 0.7791 | 8.48 | 0.3843 | 218.65 | -0.6105 | 5.78 | 37.46 | 17.10 | 5.53 | -- |
| Daiichi Sankyo Co Ltd | 10.90bn | 1.71bn | 39.28bn | 19.77k | 23.02 | 4.13 | 18.66 | 3.60 | 155.87 | 155.87 | 994.10 | 869.69 | 0.5454 | 0.8726 | 4.24 | 95,434,150.00 | 8.55 | 5.72 | 10.87 | 7.11 | 77.96 | 72.15 | 15.68 | 11.03 | 1.85 | -- | 0.0876 | 49.57 | 17.77 | 13.95 | 44.47 | 17.77 | 29.01 | 20.79 |
| Takeda Pharmaceutical Co Ltd | 26.48bn | 623.75m | 40.57bn | 47.46k | 66.01 | 1.00 | 8.07 | 1.53 | 66.83 | 66.83 | 2,880.43 | 4,407.01 | 0.3121 | 1.30 | 7.25 | 96,545,170.00 | 0.7367 | 1.71 | 0.8815 | 2.04 | 65.51 | 67.66 | 2.36 | 5.99 | 0.5202 | 2.52 | 0.3943 | 123.75 | 7.45 | 6.84 | -25.08 | 19.53 | 9.82 | 1.72 |
| Sun Pharmaceutical Industries Ltd | 5.25bn | 1.09bn | 40.81bn | 43.00k | 37.39 | 5.66 | 30.15 | 7.77 | 45.55 | 45.55 | 219.13 | 300.99 | 0.5921 | 1.07 | 4.33 | 12,227,540.00 | 12.36 | 9.09 | 15.83 | 12.38 | 79.56 | 73.38 | 20.88 | 16.07 | 2.33 | 272.98 | 0.0316 | 39.34 | 8.42 | 9.87 | 14.12 | 23.76 | 6.66 | 31.95 |
| Jiangsu Hengrui Pharmaceuticals Co Ltd | 3.50bn | 819.85m | 44.13bn | 20.24k | 53.46 | 7.84 | -- | 12.61 | 1.08 | 1.08 | 4.61 | 7.37 | 0.598 | 1.81 | 6.05 | 1,442,469.00 | 14.02 | 12.67 | 15.31 | 14.00 | 85.50 | 85.64 | 23.45 | 20.06 | 9.98 | -- | 0.0023 | 23.84 | 22.63 | 3.74 | 47.28 | 3.53 | 28.53 | 4.60 |
Data as of Jul 18 2025. Currency figures normalised to Ucb SA's reporting currency: Euro EUR
22.95%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 02 Jul 2025 | 12.79m | 6.58% |
| Wellington Management Co. LLPas of 14 May 2024 | 12.75m | 6.56% |
| The Vanguard Group, Inc.as of 02 Jul 2025 | 4.58m | 2.36% |
| BlackRock Investment Management (UK) Ltd.as of 07 Jul 2025 | 3.07m | 1.58% |
| Norges Bank Investment Managementas of 31 Dec 2024 | 2.90m | 1.49% |
| BlackRock Fund Advisorsas of 03 Jul 2025 | 2.42m | 1.24% |
| Jennison Associates LLCas of 03 Jul 2025 | 1.84m | 0.95% |
| BlackRock Advisors (UK) Ltd.as of 04 Jul 2025 | 1.47m | 0.76% |
| Eleva Capital SASas of 31 Dec 2024 | 1.46m | 0.75% |
| Geode Capital Management LLCas of 10 Jul 2025 | 1.35m | 0.69% |
More ▼
Data from 31 Dec 2024 - 31 Mar 2025Source: FactSet Research Systems Inc.
